Powder: -20°C for 3 years | In solvent: -80°C for 1 year
UGT8-IN-1 is a brain-permeable and orally-active inhibitor that specifically targets the ceramide galactosyltransferase enzyme (UGT8). By inhibiting UGT8, this compound has the potential to be employed in research pertaining to lysosomal storage disorders.
Description | UGT8-IN-1 is a brain-permeable and orally-active inhibitor that specifically targets the ceramide galactosyltransferase enzyme (UGT8). By inhibiting UGT8, this compound has the potential to be employed in research pertaining to lysosomal storage disorders. |
In vivo | UGT8-IN-1 (compound 19) demonstrates varied half-lives—4.3 hours, 1.13 hours, and 13.6 hours—in rats, mice, and dogs, respectively, following intravenous administration at a dosage of 1 mg/kg. When administered orally at a dosage of 3 mg/kg, its bioavailability (F%) is 40%, 34%, and 52% in rats, mice, and dogs, respectively. Additionally, with twice-daily oral administration at doses of <3 mg/kg for three consecutive days, it achieves over 90% inhibition of 13C-Gal incorporation into GalCer and SFT, indicating potent efficacy with estimated ED50s of <3 mg/kg for both targets. UGT8-IN-1 also exhibits extensive plasma protein and tissue binding, exceeding 99%. |
Synonyms | UGT8-IN-1 |
Molecular Weight | 528.47 |
Formula | C20H22F6N4O4S |
CAS No. | 2414349-93-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
UGT8-IN-1 2414349-93-0 UGT8 IN 1 UGT-8-IN-1 UGT8IN1 inhibitor inhibit